Original Article
Synthesis and Evaluation of Anticancer Activity of
1, 3, 4-Oxadiazole Derivatives against Ehrlich Ascites
Carcinoma Bearing Mice and Their Correlation with
Histopathology of Liver
Partha Pratim Roy1, Shalini Bajaj1, Tapan Kumar Maity2, Jagadish Singh1*
1
2
Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya, Koni, Bilaspur, Chhattisgarh, INDIA.
Department Of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, INDIA.
ABSTRACT
A series of 2, 5-disubstituted 1, 3, 4-Oxadiazole derivatives (4A-4G) have been
synthesized with the help of different aromatic benzaldehyde and final compounds
were characterized by FT-IR, 1H NMR and Mass spectroscopy. The anticancer study
was investigated against Ehrlich Ascites Carcinoma (EAC) bearing albino mice. The
synthesized (4A-4G) compounds were administered intraperitoneally at dose of 20-25 mg/kg;
body weight per day for 7 days after 24 hour of tumor inoculation in mice. The standard
compound used was 5-FU (20 mg/kg; body, weight). Synthesized compounds (4A-4G)
remarkably decreased the body weight, tumor volume, packed cell volume, viable cell
count and increased in tumor weight (%) inhibition, tumor cells (%) inhibition, the life
span, nonviable cell count of EAC tumor bearing mice when compared with the control
group. The liver section of EAC treated control group (II) was compared with the drug
treated groups (III-X). The histopathological observations of test groups suggested that
normal architecture of liver nucleus, parenchyma, and hepatic cells were regenerated,
which was damaged in EAC control group. All the synthesized compounds (4A-4G)
showed significant anticancer activity in EAC bearing mice which encourages us to
develop/improve similar other compounds and test them for their anticancer activity.
Key word: Synthesis, 1, 3, 4 oxadiazole, EAC cell, Anticancer activity, FT-IR, NMR.
Submission Date: 30-08-2016;
Revision Date: 17-11-2016;
Accepted Date: 23-11-2016
INTRODUCTION
Cancer ranked second to cardiovascular
disease as a cause of mortality it is likely to
become the most common disease in the
near future.1 In modern medicine, chemotherapy, radiotherapy and surgery are the
chief modes of cancer treatment. Chemopreventive agents have a narrow margin of
safety and the therapy may fail due to drug
resistance and dose limiting toxicities, which
may severely affect the host normal cells.2
Therefore, identification of novel potent,
less toxic and selective mechanism of action
anticancer agents remains one of the most
imperative health problems.3
1,3,4-Oxadiazoles are an important class of
heterocyclic compounds4 with a broad range
of biological activities such as anti-inflamma260
tory, analgesic and ulcerogenicity,5 apoptosisinducer,6 antimycobacterial,7 antifungal,8
antitumor,3,6,9 P-Glycoprotein Inhibitors,10
pesticides and insecticides,11 4-Hydroxylase
Inhibitors,12 anticonvulsant activity13 etc.
Moreover, it is considered that the presence
of toxophoric –N=C–O– linkage14 in 1, 3,
4-oxadiazole ring might be responsible for
their potent pharmacological activities.
Further1, 3, 4-oxadiazole heterocyclic are
very good bioisosters of amide and ester
functionalities with substantial improvement
in biological activity by participating in
hydrogen bonding interactions with different
receptor.15,16
DOI: 10.5530/ijper.51.2.31
Correspondence:
Dr. Jagadish Singh,
Assistant Professor, Institute
of Pharmaceutical Sciences,
Guru Ghasidas Vishwavidyalaya, Koni, Bilaspur,
Chhattisgarh, INDIA.
E-mail: jagadishpharm09@
gmail.com
www.ijper.org
Indian Journal of Pharmaceutical Education and Research | Vol 51 | Issue 2 | Apr-Jun, 2017
Partha et al.: Synthesis and Evaluation of Anticancer Activity of 1, 3, 4-Oxadiazole Derivatives
Schiff bases containing the >C= N group are known to
have antitumor activity, more of this compounds have
been synthesized in order to find greater antitumor
activity.17 Thus the present investigation was designed
to report some new derivatives of oxadiazole containing
>C= N group at its 2 position. Considering the potential
of this class of compounds some new 2, 5, disubstituted
1, 3, 4-oxadiazole derivatives were synthesized (4A-4G)
as showed in Scheme -1, studied for their anticancer
activity and histopathological study of liver was performed.
Chemistry
Semicarbazone (2A-2G) were synthesized by using
different aromatic aldehyde (1A-1G), semicarbazide
hydrochloride and sodium acetate. (Vogel’s, 1996) .Then
2-Amino-5-aryl-1, 3, 4-oxadiazole (3A-3G) was prepared
by using Semicarbazone (2A-2G), sodium acetate and
bromine in glacial acetic acid with the help of Magnetic
stirring. 2-Amino-5-aryl-1, 3, 4-oxadiazoles were
refluxed with required aromatic aldehyde (5-6 hours) in
ethanol to form final Schiff bases of 2-amino-5-aryl-1,
3, 4-oxadiazoles (4A-4G) derivatives then the final
compound was dried and recrystallized from alcohol.
The structures of these compounds were characterized
by FT-IR, 1H NMR and LC MS/MS Mass spectroscopy.
was filtered and recrystallized from alcohol. (Vogel’s,
1996).
2-Amino-5-aryl-1, 3, 4-oxadiazoles [3A-3G]
Semicarbazone (2A-2G) (0.01 M) and sodium acetate
(0.02 M) were dissolved in 30–40 ml of glacial acetic
acid taken in a (100 ml) round-bottomed flask equipped
with a separating funnel for the addition of bromine.
Bromine (0.7 ml in 5 ml glacial acetic acid) was added
drop by drop, while stirring magnetically. After half an
hour stirring, the solution was poured on crushed ice.
The resulting solid was separated, dried and recrystallized from aldehyde free ethanol.18
Schiff bases of 5-aryl-2-substituted-1,
4-oxadiazoles [4A-4G]
3,
A solution of [3A-3G] (0.01 M) was taken in 20 ml alcohol
a round-bottomed flask. Required aldehyde (0.01M)
dissolved in 15 ml alcohol was then added to it. The
mixture was refluxed for 5–6 h. The volume of alcohol
was reduced to half by distillation under reduced
pressure. The resulting solution was poured on crushed
ice. The precipitate was separated, dried and recrystallized from alcohol.9
MATERIALS AND METHODS
General
All the chemical (synthetic grade) were procured from
Merck, SRL and SD Fine Chemicals. Melting points
were determined in open glass capillaries and are uncorrected (VEEGO, VMP-DS). The purity of compounds
was checked by TLC on micro plates using Silica-gel-G,
solvent system chloroform: methanol (6: 1) with detecting
agent. Infrared spectra in KBr were recorded on
Shimazdzu 470 Infrared Spectrophotometer. 1H NMR
spectra were recorded on a Brucker DPX (300 MHz)
NMR spectrometer in DMSO-d6 using TMS as an internal
reference, chemical shifts are expressed in (ppm) and
mass were recorded on (API-2000) LCMS/MS. All the
compounds have given satisfactory 1H NMR, Mass and
FT- IR spectra.
Synthesis
Semicarbazone [2A-2G]
Semicarbazones were synthesized by using different
aromatic aldehyde (1A-1G) (0.5g), semicarbazide hydrochloride (1.0 g) and sodium acetate (1.50 g) were taken
in 100 ml conical flask and dissolved in 30-40ml of
distilled water. After half an hour stirring, the precipitate
Scheme 1 Synthetic pathway for compounds 4A-4G
Compound
R1
R2
4A.
4 -OH,
4’ -N (CH3)2
4B
2 -CI
2’ -NO2
4C
3 -Br
4’ -CI
4D
4 -N (CH3)2,
4’ -N (CH3)2
4E
2-CI,
4’ -N (CH3)2
4F
3 -Br
4’ -OH
4G
4 -OCH3,
Indian Journal of Pharmaceutical Education and Research | Vol 51 | Issue 2 | Apr-Jun, 2017
4’ -N (CH3)2
261
Partha et al.: Synthesis and Evaluation of Anticancer Activity of 1, 3, 4-Oxadiazole Derivatives
Compound:4A.[5-{-4-Hydroxy-Phenyl)-2-imino-(4-dimethyl-amino-phenyl) 1, 3, 4- Oxadiazole]
(C): M.P: 220-221-O C. Yield: 70%. Chemical formula:
C17H16 O2N4. FT-IR (cm -1): 3452, 3283 (ArC-OH);
2913, 3068, 3154 (ArC-H); 1657 (C=N), 1250 (C-O-C),
1601 (C=C), 1438, 1509 ( N=CH). 1H NMR (300
MHZ, DMSO d6 p p m): δ 10.08 (S, 1H, N=CH): δ 7.74
( d, 2H, J= 9Hz, ArH 2, 3); δ 7.66 ( d, 2H, J= 9Hz, ArH
4, 5,); δ 2.93-2.85 ( d, 6H, N(CH2 )2 ); δ 7.13-7.06
(m, 4H, ArH); δ 9.91 (s, 1H, OH). m/z: 310.50/308.50
(M+ /M-).
Compound: 4B. [5-{(-2-Chloro-Phenyl)-2-imino-(2-nitro-phenyl)}-1, 3, 4- Oxadiazole] : M. p: 214216 O C. Yield: 80%. Chemical formula: C15H9 O3N4CI.
FT-IR (cm -1): 2991 (ArCH), 1515 (ArC-NO2 ), 742(
ArC-CI), 1658 (C=N), 1280 (C-O-C), 1600(C=C),
1426, 1515 (N=CH). 1H NMR (300 MHZ, DMSO d6 p
p m): δ 10.48.(S, 1H, N=CH); δ 6.57-7.46 (m, 4H, ArH
2’3’ 5’ 6’); δ 8.23-8.17 (m, 4H, ArH 2, 3, 4, 5,). m/z:
329.50/327.50( M+ /M-).
Compound: 4C. [5-{(3-Bromo-Phenyl)-2-imino(4-chloro-phenyl)}-1, 3, 4-Oxadiazole]: M. p: 222224O C. Yield: 75%. Chemical formula: C15H9 ON3BrCI.
FT-IR (cm -1): 2991, 3068 (ArC-H); 1682 (C=N), 1220
(C-O-C), 1600 (C=C) 1426, 1515 (C=NH), 851,742
(ArC-CI), 562, 627 (ArC-Br),. 1H NMR (300 MHZ,
DMSO d6 p p m): δ 10.35 (S, 1H, N=CH); δ 7.52
(d, 2H, J= 6Hz, ArH 2’ 3’ ); δ 7.35 (d, 2H, J= 6Hz, ArH
5’, 6’,); δ 8.06 (S 1H, ArH , 2); δ 7.78 (s, 1H, ArH, 4);
δ 7.30-7.35 ( t, 1H, ArH 5); 6.60( s 1H, ArH, 6).
Compound: 4D. [5-{-4-dimethyl amino-Phenyl)2-imino-(4-dimethyl amino-phenyl) 1, 3, 4- Oxadiazole]: M.P: 185-187O C. yield-70%. Chemical formula:
C19H21 ON5. FT-IR (cm -1): 2938, 3153 (ArC-H); 1682
(C=N), 1221 (C-O-C), 1558 (C=C), 1435, 1493
( N=CH). 1H NMR (300 MHZ, DMSO d6 p p m):
δ 10.20 (S, 1H, N=CH); δ 2.96-2.93 ( d, 6H, N(CH2 )2 );
δ 3.34 (s, 6H, N(CH2 )2 ); δ 6.79 ( d, 2H, J= 9Hz,
ArH 2 , 3 ); δ 6.70 ( d, 2H, J= 9Hz, ArH 5 ,6 ); δ 7.56748.(m, 4H, ArH 2’, 3’, 4’, 5’,).
Compound: 4E. [5-{ 2 Chloro-Phenyl)-2-imino(4-dimethylamino-phenyl) 1, 3, 4- xadiazole] : M.P:
173-175-O C. Yield: 61%. Chemical formula: C17H15
ON4CI. FT-IR (cm- 1): 3134 (ArC-H), 1651 (C=N),
1253 (C-O-C), 1507 (C=C), 1439, 1357 ( N=CH),
765(ArC-Cl). 1H NMR (300 MHZ, DMSO d6 p p m):
δ 10.50 (S, 1H, N=CH); δ 8.23-8.18 ( m, 4H, ArH 3,
4, 5, 6); δ 7.69 (d, 2H, J= 6Hz, ArH 2’, 3’ ); δ 7.35 (d,
2H, J= 6Hz, ArH 5’, 6’ ); δ 3.04 ( s, 6H, N(CH3)2). m/z:
327.50/325.50( M+ /M-).
Compound: 4F. [5-{( 3-Bromo-Phenyl)-2-imino(4-hydroxy-phenyl)}-1, 3, 4-Oxadiazole]: M. p: 222262
224O C. Yield: 55%. Chemical formula: C15H10 O2N3Br.
FT-IR (cm -1): 3463 (Ar-OH) 2984, 3062 (ArC-H); 1699
(C=N), 1227 (C-O-C), 1584 (C=C) 1471, 1443 (C=NH),
559, 680 (ArC-Br),.1H NMR (300 MHZ, DMSO d6
p p m): δ 10.36 (S, 1H, N=CH); δ 7.78-7.76 (d, 2H,
J= 6Hz, ArH 2’ 3’ ); δ 7.48-7.46 (d, 2H, ArH 5’, 6’,);
δ 7.89 (S 1H, ArH , 2); δ 7.71-7.69 (d, 1H, J= 6Hz,
ArH, 4); δ 7.64-7.62 ( d, 1H, J= 6Hz, ArH, 6); 7.36-7.31
( t 1H, ArH, 5); δ 8.06 (s, IH, OH). m/z: 344.90/342.90
(M+ /M-).
Compound: 4G.[5-{(4 Methoxy-Phenyl)-2-imino-(4amino-dimethyl-phenyl)}-1, 3, 4- Oxadiazole]:
M. p: 218-221 O C. yield-71%. Chemical formula: C18H18
O2N4.. FT-IR (cm -1): 3111 (ArCH), 1657 (C=N),
1077 (C-O-C), 1503 (C=O), 1563 (C=C), 1474, 1515
(C=NH). 1H NMR (300 MHZ, DMSO d6 p p m):
δ 8.57. (S, 1H, N=CH): δ 1.58 (s, 3H, CH3O); δ 3.84-3.93
(d, 6H, N ( CH3)2); δ 6.98 (d, 2H, J= 9Hz, ArH 2’ 3’);
δ 6.92 (d, 2H, J= 9Hz ArH 5’ 6’ ); δ 7.57 ( d, 2H,
J=9Hz, ArH 2, 3, ); δ 7.50 ( d, 2H, J=Hz, ArH 5, 6,).
m/z: 323/321( M+ /M-).
Biological Experimental Section
Animals
Studies were carried out using male Swiss albino mice
of about 8 weeks of age with an average body weight
of 18-20 g. The animals were obtained from animal
supplier Rita Ghosh, Kolkata, India. They were grouped
and housed in polyacrylic cages and maintained under
standard laboratory conditions (temperature 300 C) with
dark and light cycle (12/12h) and fed standard pellet
diet, fresh water ad libitum. The mice were acclimatized
to laboratory condition for 10 days before commencement of the experiment. All procedures described
were reviewed and approved by the University Animals
Ethical Committee. The recommendations of Jadavpur
University Institutional Animal Ethics Committee
[Committee for the Purpose of Control and Supervision
of Experiment on Animals (CPCSEA registration.
no. 0367/01/C/CPCSEA) India for the care and use
of laboratory animals were strictly followed throughout
the study and these were in accordance with the NIH
(USA) guidelines.
Tumor cell
A tumor cell used for anticancer activity is EAC (Ehrlich
Ascites Carcinoma) cells originated from human breast
carcinoma. It is an undifferentiated tumor, which has
lost its epithelial character. Ehrlich Ascites Carcinoma
(EAC) cells were obtained from Chittaranjan National
Cancer Institute, Kolkata, India. The (EAC) cells
were maintained in vivo in Swiss albino mice by intra
Indian Journal of Pharmaceutical Education and Research | Vol 51 | Issue 2 | Apr-Jun, 2017
Partha et al.: Synthesis and Evaluation of Anticancer Activity of 1, 3, 4-Oxadiazole Derivatives
peritoneal inoculation of 2 ×106 cells/ mouse after
10 days. EAC cells of 9 days old were used for screening
of the compounds.
Experimental procedure
Male Swiss albino mice of 8 weeks old with an average
body weight of 18 to 20 g were used. All mice were
kept on basal metabolic diet with water ad libitum. Male
Swiss albino mice were divided into 10 groups (n = 12).
EAC cells are collected from the donor mice and are
suspended in sterile isotonic solution (0.9% w/v NaCl).
The numbers of tumor cells per ml of this suspension
are counted under microscope with the help of hemocytometer. All the groups were treated with EAC cells
(0.2 ml of 2 ×106 cells/mouse) intraperitoneally except
the normal group. This was taken as day zero. In this
instance, the tumor cells multiply relatively freely within
the peritoneal cavity and ascites develops. A day of incubation allows for establishing the disease in the body
before starting the drug administration. On the first day,
5 ml/kg body weight of normal saline (0.9% NaCl W/v)
was administered in group I (Normal). Normal saline
5ml/kg; body weight per day was administered
in-group II (EAC control). The synthesized compounds
(4A-4G were administered at dose of 25, 20, 20, 25, 20,
20, 25mg mg/kg; body weight/day) and the standard
drug 5-Fluorouracil (20 mg/kg; body weight/day) was
administered in groups (III-IX) and (X) respectively for
7 days intraperitoneally at 24 hr interval. Thus 7 doses
of the drug are administered to each mouse in the test
group. On the 9th day food and water were with hold
18 hr before the starting the testing operation. The
weight of all the animals was recorded before they are
sacrificed. The peritoneal cavity was dissected and by
a syringe the ascitic fluid was withdrawn to a suitable
volume, collected in sterile ice-cold saline and preserved
in ice bath. The total number of living cells/ml in the
peritoneal fluid of 6 mice in a group was calculated. The
fluid is sucked by adsorbent cotton. The weight of
6 mice after sacrifice was recorded and remaining
animals kept for observation of life span of the hosts.
The evaluation of the test drug is made by comparing
the cell count of the test with that of the control. The
percentage inhibition of cell count is obtained by
following expression: (TCI) = (1-T/C) ×100, where
T is the average number of Ascitic cells /ml in test
animals, C is the average number of the Ascitic cells /ml
in control animals.
The anti-tumor activity of the compounds was measured in EAC animals with respect to the following
parameters such as: Body weight, Tumor weight, Tumor
cell count, Tumor growth response, Tumor volume,
Viable and non viable tumor cell count, Mean survival
time and percentage increase in life span, Hematological
studies.19-23
Acute Toxicity study: Male Albino mice of 10 animals
per group and weighting between 18-20g were administered with graded doses of (50 -300 mg/kg, Body
weight, i. p) of the synthesized compounds (4A-4G).
Death of the animals was observed 48h treatment of
the administered synthesized (4A-4G) compounds. The
toxicological effects were observed in terms of mortality
and expressed as LD50 (Ghosh et al., 1984). During the
experiment on above said dose regimen 50% death was
observed of synthesized compounds( 4A-4G) respectively (250, 200, 200, 250, 2000, 200, 250mg/kg, Body
weight, i. p). From present study it could be concluded
that synthesizes compounds (4A-4G) were safe unto 25,
20, 20, 25, 20, 20, 25mg/kg body weight i. p.
RESULT AND DISCUSSION
Cancer is a pathological state where uncontrolled
proliferation of the cancer cells is found. The anticancer
properties of the synthesized compounds were evaluated by measuring their ability to inhibit cancer cell
growth in ascitic fluid of Swiss albino mice. Percentage
tumor weight inhibition (% TWI) and percentage inhibition of ascitic cells or percentage of tumor cell count
inhibition (%TCI) were measured on treated EAC cells
when compared to untreated control cells. Compounds
(4A-4G) having anticancer potential are shown in the
Table 1. Among all the test compounds, compound 4E
exhibited highest tumor weight inhibition (73.15%) and
tumor cell count inhibition (65.07%) at the dose of
20 mg/kg; body weight, (i.p.) as compared to control.
Standard drug showed about 95.78% tumor weight
inhibition and 96.09 % tumor cell count inhibition.
The rest of the compounds showed 57.63%, 60.52%,
60.52%, 62.63%, 62.63% and 63.68% of % TWI and
39.35%, 50.41%, 52.00%, 57.01%, 58.87% and 60.17%
of % TCI respectively. According to the standard of
National Cancer Institute, a substance is considered
active if it exhibits the tumor growth inhibition of
50 %. All the tested compounds were found to show
inhibition of tumor growth above 50 % (except
compound 4D) which supports the efficacy of the
oxadiazole derivatives to serve as potent anti cancer
agents against EAC cells.
In EAC bearing mice a regular rapid increase in ascites
tumor volume was observed. Ascites fluid is considered
to be direct nutritional source for tumor cells and a rapid
increase in ascites fluid with tumor growth would be a
means to meet the nutritional requirement of tumor
Indian Journal of Pharmaceutical Education and Research | Vol 51 | Issue 2 | Apr-Jun, 2017
263
Partha et al.: Synthesis and Evaluation of Anticancer Activity of 1, 3, 4-Oxadiazole Derivatives
Table 1: Results of anticancer activity of the tested (A-G) compounds on % TWI and %TCI.
Group
Compounds
Dose of drug
(mg /kg)
Avg tumor weight
(g)
% TWI
Avg cell count
(Number)
%TCI
I
Normal Control
-------
------
--------
------
--------
II
Induced control
--------
1.90
0.00
79.96 ± 0.28
0.00
III
A
25
0.75 ± 0.00*
60.52
38.38 ± 0.51*
52.00
IV
B
25
0.71 ± 0.00*
62.63
34.35 ± 0.53*
57.01
V
C
25
0.75 ± 0.00*
60.52
31.86 ± 0.43*
60.15
VI
D
25
0.81 ± 0.00*
57.63
52.49 ± 0.62*
39.35
VII
E
25
0.51 ± 0.00*
73.15
27.96 ± 0.51*
65.07
VIII
F
25
0.69 ± 0.00*
63.68
32.88 ± 0.48*
58.87
IX
G
25
0.71 ± 0.00*
62.63
39.65 ± 0.25*
50.41
X
5-Fluorouracil
20
---------
95.78
--------
96.09
Value are Mean ± SEM. n=6 animal in each group. *P< 0.05 is considered significant when III, IV, V, VI, VII, VIII, IX, groups were compared
with group II. (When considered both Avg Tumor weight and Avg Cell count).
cells.23,24 This might be the possible reason that the
EAC cell-bearing mice (group II) showed a significant
increase in body weight as compared with the normal
mice in group-I (negative control).
5-Flurouracil treated group and test compounds (4A-4G)
treated groups showed a significant (p<0.001) reduction
in the body weight of EAC cell-bearing mice when
compared with EAC control. The drugs decreased the
tumor volume, packed cell volume, viable cell count and
increased the life span, percentage of trypan blue positive
stained dead cells in tumor bearing mice (Table 2).
Results for the test compound indicate that there is
decrease in the nutritional fluid volume, arresting the
tumor growth and the prolongation of the life span of
animals and might be act as antineoplastic agents.
A complete blood count provides detailed information
about three types of blood cells: red blood cells (RBC),
white blood cells (WBC) and platelets. These blood cells
are made in the bone marrow. Furthermore, hematological characteristics have been widely used in the
diagnosis of variety of diseases (like cancer) and pathologies induced by industrial compounds, drugs, dyes,
heavy metals, pesticides and several others.25,26,28,29
RBC (known as erythrocytes) is very important for the
transport of oxygen from the lungs to the tissues and
hemoglobin concentration is directly correlated with
the RBC count. This close correlation between erythrocyte count and haemoglobin concentration was also
reported for other vertebrates including man.30
WBC formed in the bone marrow either enters the
blood or migrates to key organs such as the spleen,
lymph nodes, or gut. The increased number of leukocytes
can occur abnormally as a result of an infection, cancer,
264
or toxic chemical. Such increase of WBC may be due to
the activation of the defense mechanism of animals and
their immune system.27
Myelosuppression and anemia are the two major
problems in cancer chemotherapy.24 (Price et al., 1958;
Hogland HC et al., 1982) The anemia in tumor bearing
mice is mainly due to reduction in RBC or hemoglobin
percentage and increase in WBC and this may occur
either due to iron deficiency or due to hemolytic or
myelopathic conditions or due to cancer. Treatment
with (4A-4G) brought back significantly (p<0.05) the
hemoglobin (Hb) content, RBC and WBC count more
or less to normal levels. He differential count and the
percentage of neutrophil was increased, while the
lymphocytes count was decreased in synthesized
compounds treated groups bearing EAC cell lines when
compared with EAC control mice. Other parameters
like HCT (%), MCV (fl), MCH (Pg), MCHC (g/ dL),
PLT (109 / L) were showen in Table 3. This clearly
indicates that synthesized (4A-4G) compounds possess
protective action on the hemopoietic system.
Carcinogenesis is associated with cirrhosis and cirrhosis
correlates with primary liver disease. Liver is easily
affected by various types of diseases, cancer being one
of them. EAC easily affects the liver of mice. From the
experiment the liver section of EAC treated control
group was compared with normal, 5-Flurouracil and
drug treated groups (4A-4G). The histopathological
observations of test groups suggested normal architecture of liver tissue, less thick wall central vein (CV),
deformed necrosis of tissue (N) and nucleus, parenchyma,
hepatic cells were regenerated, which was damaged
in EAC treated control group. (Figure 1A-10)
Indian Journal of Pharmaceutical Education and Research | Vol 51 | Issue 2 | Apr-Jun, 2017
Parameter
Group-II
Group-III
Group-IV
Group-V
Group-VI
Group-VII
Group-VIII
Group-IX
Group-XI
EAC+(2×106cell/
ml per mice)
EAC+A
(25mg/kg)
EAC+B
(25mg/kg)
EAC+C
(25mg/kg)
EAC+D
(25mg/kg)
EAC+E
(25mg/kg))
EAC+F
(25mg/kg)
EAC+G
(25mg/kg)
EAC+5-FU (20mg/
kg)
Body weight(g)
22.54±0.012
19.31±0.004*
19.16±0.006*
19.96±0.012*
20.27±0.010*
18.90±0.004*
19.18±0.005*
19.56± 0.004*
18.19± 0.004*
Mean survival time
(days)
16.50±84
31.78±0.44*
35.33±0.50*
36.00±73*
26.16±87*
36.33±80*
35.66±84*
28.00±0.89*
41.50±0.71*
Increase in life
span(%ILS)
---------
92.60
114.12
118.18
58.54
120.18
116
69.69
151.51
Tumor volume(ml)
1.19±0.06
0.77±0.02*
0.73±0.04*
0.60±0.02*
0.90±0.01*
0.40±0.01*
0.63±0.27*
0.83±0.02*
--------
Pack cell volume(ml)
0.85±0.01
0.36±0.01*
0.30±0.00*
0.13±0.00*
0.56±0.02*
0.10±00*
0.13±0.00*
0.46±0.02*
----------
Viable cell
count(×106 cells/ml)
74.27±0.51
28.00±0.57*
24.32±0.53*
21.34±0.43*
42.06±0.62*
15.37±0.51*
20.50±0.56*
28.13±0.94*
--------
Non-viable cell
count(×106 cells/ml)
5.69±0.28
10.38±0.63*
10.03±0.37*
10.52±0.34*
10.43±0.20
12.56±0.48*
12.38±0.25*
11.52±0.43
---------
Value are Mean ± SEM. n=6 animal in each group. * P<0.01 is considered significant when (III), (IV), (V), (VI), (VII), (VII), (IX), (X) groups were compared with EAC control group (II).
Table 3: Results of anticancer activity of the tested (A-G) compounds on hematological parameters.
Parameter
Hemoglobin (g %)
12/
Group-I
Group-II
Group-III
Group-IV
Group-V
Group-VI
Group-VII
Group-VIII
Group-IX
Normal control
(0.9%NaCI ml/
mice)
EAC control
(2×106cell/ml
per mice)
EAC +
Compound A
(25mg/kg)
EAC +
Compound B
(25mg/kg)
EAC +
Compound C
(25mg/kg)
EAC +
Compound D
(25mg/kg)
EAC +
Compound E
(25mg/kg)
EAC +
Compound F
(25mg/kg)
EAC + Compound
G
(25mg/kg)
13.30±0.06*
9.04±0.49
10.57±0.50*
10.28±0.23*
10.96±0.59*
9.74±0.30*
12.32±0.30
11.25±0.39*
10.60±0.32*
RBC(×10 L)
9.53±0.01*
3.84±0.05
6.76 ± 0.07*
5.78±0.07*
6.25±0.10*
4.56±0.04
7.56±0.05*
7.13±0.03*
6.74±0.16*
WBC(×109/L)
5.36±0.07*
19.10±0.04
10.06±0.04*
11.35±0.12*
10.13±0.05*
14.13±0.06*
8.41±0.31*
9.06±0.02*
9.90±0.18
Monocyte (%)
1.93±0.00*
1.06±0.02
1.52±0.01*
1.63±0.06*
1.50±0.05*
1.25±0.00*
1.71±0.01*
1.34±0.00*
1.41±0.00*
Neutrophil(%)
17.97±0.00*
80.79±0.34
51.42±0.33*
55.96±0.17*
58.12±0.25*
71.70±0.35*
33.25±0.08*
61.91±0.0.47*
64.60±0.23*
Lymphocyte (%)
81.23±0.05*
24.11±0.09
48.53±0.30*
56.31±0.00*
67.98±0.17*
38.84±0.41*
73.31±0.07*
70.02±0.29*
45.28±0.08*
HCT (%)
39.29±0.26*
28.48±0.12
35.19±0.43*
31.39±0.41*
35.52±0.47*
31.45±0.30*
37.21±0.63
35.74±0.41
34.01±0.22*
MCV( fL)
78.52±0.19*
39.22±0.37
46.22±0.25*
44.65±0.14*
44.91±0.29*
40.11±0.25*
64.79±0.51*
59.23±0.11*
51.34±0.09*
MCH( Pg)
29.19±0.15*
11.24±0.05
15.29±0.03*
14.73±0.08*
14.64±0.08*
13.02±0.21*
25.12±0.06*
22.25±0.07*
16.08±0.04*
MCHC(g/dL)
35.79±*
30.28±0.28
32.87±0.05*
33.34±0.09*
33.16±0.23*
30.97±0.17*
34.56±0.18*
33.28±0.32*
32.81±0.17*
PLT( 109 / L)
410.50±0.42*
297.50±0.42
335.50±0.61*
350.16±0.47*
340.50±0.42*
301.16±0.30*
387.83±0.47*
351.66±0.42*
340.50±0.42*
265
Value are Mean ± SEM. n=6 animal in each group. *P< 0.05 is considered significant when (I), (III), (IV), (V), (VI), (VII), (VIII), (IX) groups were compared with EAC control group (II). Hb: Hemoglobin, RBC: Red Blood Cells, WBC: White Blood
Cells, M: Monocyte, N: Neutrophils, L: Lymphocytes, HCT: Hematocrit, MCV: Mean Corpuscular Volume, MCH: Mean Corpuscular Hemoglobin, MCHC: Mean Corpuscular Hemoglobin Concentration, PLC: Platelet Count.
Partha et al.: Synthesis and Evaluation of Anticancer Activity of 1, 3, 4-Oxadiazole Derivatives
Indian Journal of Pharmaceutical Education and Research | Vol 51 | Issue 2 | Apr-Jun, 2017
Table 2: Results of anticancer activity of the tested (A-G) compounds on mean survival time (MST), increase in life (%ILS), tumor volume, packed cell
volume, cell count.
Partha et al.: Synthesis and Evaluation of Anticancer Activity of 1, 3, 4-Oxadiazole Derivatives
Figure 1A: The liver section of the normal mice was composed of a number of lobules and hepatic tissue showing a
thin walled central vein (CV) from which cords of hepatic cells
radiate. Branches of the hepatic portal vein (PV), hepatic
artery (A) and bile ductules (BD) forming the portal triads are
also seen (×100).
Figure 2: Photomicrograph of mice liver in EAC treated with
5-Fluorouracil showing more or less normal structure of the
liver tissue, showing thin wall central vein(CV), hepatic portal
vein (PV) and large neoplastic hepatocytes (N) are
regenerated look like to normal liver section ( ×100).
Figure 10: Photomicrograph of mice liver in control group
showing thick walled central vein (CV) plates of highly
differentiated, large neoplastic hepatocytes (N) (prominent
nucleoli and finely granular cytoplasm) without discernible
hepatic architecture (× 100).
Figure: 3, 4, 5, 6, 7, 8 & 9 Photomicrograph of mice liver in
EAC treated with drugs (4A-4G) showing more or less
structural damages of the liver tissue, showing damage
central vein(CV), degenerated hepatocytes and deformed
necrosis of tissue (N)(× 100).
Structural features of the synthesized compounds
for their antitumor activity
In general, the anti cancer activity seemed to be dependent on the nature of the substituents rather the basic
skeleton of the molecule.33 Within the Oxadiazole series
it was noticed that the substituent at the position 5 had
great influence on the anticancer activity. Substitution
with various pharmacophore at this position may give
rise to the novel molecules with enhanced anticancer
properties.
The Study indicates that groups like 4-hydroxy-phenyl
(4A) 3-bromo phenyl(4C, 4F), 2-chloro phenyl(4B, 4E)
substituent at 5-position and 2-nitrophenyl(4B), 4-chlorophenyl (4C), 4-hydroxy phenyl (4F) substituent at
position 2 linking by im ino bridge to 1, 3, 4-oxadiazole
showed significant anti-tumor activity.
266
The activity of the compounds get increased due to the
attachment of the phenyl ring with the substitution of
the electron withdrawing/donating group at 5th position
of the Oxadiazole ring and also due to the presence of
the N=CH linked Schiff base side chains at 2 position.
The exact mechanism of action of 1, 3, 4-Oxadiazole
derivatives are still unknown. The probable mechanism
may be due to multiple events, can increase percentage
inhibition of ascitic cells or percentage of tumor cell
count inhibition or act as decreasing the nutritional
fluid volume or arresting the tumor growth or act as
apoptosis inducer. A novel analog, 5-(3-chlorothiophen-2- yl)-3-(5-chloro-pyridin-2-yl)-1, 2, 4-oxadiazole
was identified as a lead compound to induce apoptosis
in vivo anticancer activity.31 Another novel series of 3,
5-[1, 2, 4]-diaryl-oxadiazoles act as apoptosis-inducer in
cancer treatment with no measurable effects on normal
cells.32 Therefore the synthesized 1, 3, 4 oxadiazole com-
Indian Journal of Pharmaceutical Education and Research | Vol 51 | Issue 2 | Apr-Jun, 2017
Partha et al.: Synthesis and Evaluation of Anticancer Activity of 1, 3, 4-Oxadiazole Derivatives
pounds with the above mentioned substituents could be
a potential anticancer agent.
2-thiol and Schiff bases of Diclofenac acid as Nonulcerogenic Derivatives.
Bioorg
Med
Chem.
2008;16(4):1822-31.
https://doi.org/10.1016/j.
bmc.2007.11.014 PMid:18248993.
6.
Katayoun A, Jessen, NM, English, Wang JY, Maliartchouk S, Kasibhatla S.
The discovery and mechanism of action of novel tumor-selective and
CONCLUSION
The synthesized compounds (4G-AG) showed significant result in different parameters of EAC bearing mice
and markedly increase the average life span of experimental animals. From the present study, result indicate
that the oxadiazole compounds can potentially be developed into useful anticancer agents or further work to
develop or improve similar and related compounds and
test them for a wide range of biological activity.
apoptosis-inducing 3, 5-diaryl-1, 2, 4-oxadiazole series using a chemical
genetics approach. Mol Cancer Ther. 2005;4(5):761-71. https://doi.
org/10.1158/1535-7163.MCT-04-0333 PMid:15897240.
7.
Maria GM, Daniele Z, Luciano V, Maurizio F, Marco F, Pricl S, Scialinoc G,
Banfic E. Antimycobacterial activity of new 3-substituted 5-(pyridin-4-yl)3H-1,3,4-oxadiazol-2-one and 2-thione Derivatives Preliminary molecular
modeling investigations. Bioorg Med Chem. 2005;13(11):3797-09. https://
doi.org/10.1016/j.bmc.2005.03.013 PMid:15863006.
8.
Guang F, Yang Z, Ming L, Xiang HQ. Synthesis of 5,7-Dimethyl-2-(5Substituted-1,3,4-Oxadiazole-2-yl)-Methylenethio-1,2,4-Triazolo[1,5-a]
Pyrimidinesas Potential Fungicides. Chinese Chemical Lett. 2001;(12):877-80.
9.
Aboraia AS, Abdel-Rahman HM, Mahfouz NM and EL-Gendy MA. Novel
5-(2-hydroxyphenyl)-3-substituted-2, 3-dihydro-1, 3, 4-oxadiazole-2-thione
ACKNOWLEDGEMENT
derivatives: Promising anticancer agents. Bioorg Med Chem. 2006;14(4):1236-46.
One of the author (JS) acknowledges University Grants
Commission (UGC) for providing support by a Start up
Research Grant [No. F. 20-19(3)/2012(BSR)].
https://doi.org/10.1016/j.bmc.2005.09.053 PMid:16242340.
10.
Mishra L, Said MK, Itokawa H, Takeya K. Antitumor and antimicrobial activities
of Fe (II)/Fe (III) complexes derived from some heterocyclic compounds.
Bioorg
Med
Chem.
1995;3(9):1241-45.
https://doi.org/10.1016/0968-
0896(95)00095-X.
11.
CONFLICT OF INTEREST
Loetchutinat C, Chau F, Mankhetkorn S. Synthesis and Evaluation of 5-Aryl3-(4-hydroxyphenyl)-1, 3, 4-oxadiazole-2-(3H)-thiones as P-Glycoprotein
Inhibitors. Chem Pharm Bull. 2003;51(6):728-30. https://doi.org/10.1248/
The authors have no conflict of interest.
cpb.51.728 PMid:12808255.
12.
Shia W, Qianb X, Songa G, Zhanga R, Lia R. Syntheses and insecticidal
activities
ABBREVIATIONS USED
J
EAC: Ehrlich Ascites Carcinoma; 5FU: 5- Fluorouracil
DMSO: Dimethyl sulfoxide; FTIR: Fourier Transform Infrared; HNMR: Proton Nuclear Magnetic
Resonance; LCMS: Liquid Chromatography Mass
Spectrometry; CPCSEA: The Committee for the Purpose of Control and Supervision of Experiments on
Animals; LD50: Lethal Dose; TWI: Tumor Wight Inhibition; TCI: Tumor Cells Inhibition; HCT: Hematocrit; MCV: Mean Corpuscular Volume; MCH: Mean
Corpuscular Hemoglobin; MCHC: Mean Corpuscular
Hemoglobin Concentration; PLC: Platelet Count.
of
Fluorine
novel
Chem.
2-uorophenyl-5-aryl/cyclopropyl-1,3,4-oxadiazoles.
2000;106(2):173-79.
https://doi.org/10.1016/S0022-
1139(00)00323-7.
13.
Yamada N, Kataoka Y, Nagami T, Hong S, Kawal S, Kuwano E. 5-Aryl-1,
3,4-oxadiazole-2-thiols as a New Series of trans-Cinnamate 4-Hydroxylase
Inhibitors.
J
Pestic
Sci.
2004;29(3):205-08.
https://doi.org/10.1584/
jpestics.29.205.
14.
Zarghi A, Hamedi S, Tootooni F, Amini B, Sharifi B, Faizi M, Abbas S, Abbas
ST. Synthesis and Pharmacological Evaluation of New 2-Substituted-5-{2-[(2
halobenzyl)thio)phenyl}- 1,3,4-oxadiazoles as Anticonvulsant Agents. Sci.
Pharm. 2008;76(2):185-01. https://doi.org/10.3797/scipharm.0803-10.
15.
Rigo A, Lagrenee M. A simple and efficient procedure for synthesis of optically
active 1, 3, 4-oxadiazole derivatives containing Lamino acid moieties.
J Hetero Chem. 1999;36:1029-32.
16.
Guimaraes CRW, Boger DL, Jorgensen WL. Elucidation of Fatty Acid Amide
Hydrolase Inhibition by Potent r-Ketoheterocycle Derivatives from Monte
Carlo Simulations. J Am Chem Soc. 2005;127(49):17377-384. https://doi.
org/10.1021/ja055438j PMid:16332087.
17.
REFERENCES
1.
5-(2-hydroxyphenyl)-3-substituted-2, 3-dihydro-1, 3, 4-oxadiazole-2-thione
derivatives: Promising anticancer agents. Bioorg Med Chem. 2006;14(4):1236-46.
Mesery ME El, Gayyar MM Al, Salem HA, Darweish MM, Mowafy AM
https://doi.org/10.1016/j.bmc.2005.09.053 PMid:16242340.
El. Chemo preventive and renal protective effects for docosahexaenoic
acid (DHA): implications of CRP and lipid peroxides. Cell. Division.
2009;4(1):61-7.
https://doi.org/10.1186/1747-1028-4-6
18.
1,3,4-oxadiazole analogues. Bioorg Med Chem. 2005;13(10):3385-95.
Nitha B, Meera CR, Janardhanan KK. Anti-inflammatory and antitumour
activities of cultured mycelium of morel mushroom, Morchella esculenta.
https://doi.org/10.1016/j.bmc.2005.03.012 PMid:15934142.
19.
Ahmed SA, Abdel-Rahman HM, Mahfouz NM, Mahmoud A, EL-Gendy. Novel
5-(2-hydroxyphenyl)-3-substituted-2, 3-dihydro-1, 3, 4- oxadiazole-2-thione
jm00298a054.
20.
derivatives: Promising anticancer agents. Bioorg Med Chem. 2006;14(4):1236Rigo A, Couturier D. Studies on pyrrolidinones. Synthesis of N
Microbial. 2005;51(2):133-41. https://doi.org/10.2323/jgam.51.133.
21.
benzhydrylpyroglutamic. J Hetero Chem. 1985;22:925-30. https://doi.
Shashikant V, Bhandari KG, Bothara MK, Ajit R, Patil A, Aniket SP, Mokale VJ.
Sengupta P, Dash DK, Yeligar, VC, Murugesh K, Rajlingam D, Singh J, Maity TK.
Evaluation of Anticancer Activity of some 1, 3, 4-oxadiazole derivatives.
org/10.1002/jhet.5570220148.
5.
Mishra P, Rajak H, Mehta A. Synthesis of Schiff bases of 2-amino-5-aryl-1,
3, 4-oxadiazoles and their evaluation for antimicrobial activities. J Gen Appl
46. https://doi.org/10.1016/j.bmc.2005.09.053 PMid:16242340.
4.
Hodnett EM, Dunn WJ. Structure Antitumor Activity Correlation of Some
Schiff Bases. J Med Chem. 1970;13(4):768-69. https://doi.org/10.1021/
Current Sci. 2007;92(2):2-5.
3.
Khan MTH, Choudhury MI, Ranib KMKM, Atta-ur-Rahman. Structure–activity
relationships of tyrosinase inhibitory combinatorial library of 2, 5-disubstituted-
PMid:19341447
PMCid:PMC2680397.
2.
Aboraia AS, Abdel-Rahman HM, Mahfouz NM, EL-Gendy MA. Novel
Indian J Med Chem. 2008;47(3):460-62.
22.
Gupta M, Mazumder UK, Haldar PK, Kandar CC, Manikandan L, Senthil GP.
Design, Synthesis and Evaluation of Anti-inflammatory, Analgesic and
Anticancer Activity of Indigofera aspalathoides and Wedelia calendulaceae in
Ulcerogenicity studies of Novel S-Substituted phenacyl-1, 3, 4-oxadiazole-
Swiss Albino Mice. Iranian J Pharma Res. 2007;(6):141-45.
Indian Journal of Pharmaceutical Education and Research | Vol 51 | Issue 2 | Apr-Jun, 2017
267
Partha et al.: Synthesis and Evaluation of Anticancer Activity of 1, 3, 4-Oxadiazole Derivatives
23.
Gupta M, Mazumdar UK. Antineoplastic activities of MT81 and its structural
30.
analogue in Ehrlich Ascites Carcinoma-bearing swiss albino mice. Oxida Med
and Cellular Long. 2010;3(1):61-70. https://doi.org/10.4161/oxim.3.1.10495
24.
25.
Physiology and Pathology. Academic Press, New York. 1972;16(5):166-17.
31.
Drewe JSXC. Discovery of substituted 4-anilino-2-(2-pyridyl) pyrimidines
Gupta M, Mazumdar UK, Sambathkumar R, Sivakumar T. Antitumor activity
as a new series of apoptosis inducers using a cell- and caspase-based
and antioxidant role of Bauhinia racemosa against Ehrlich Ascites Carcinoma
high throughput screening assay. Part 1: Structure–activity relationshipsof
in swiss albino mice”. Acta Pharm Sinica. 2004;25:1070-76. PMid:15301742.
the 4-anilino group. Bioorg Med Chem. 2006;14(23):7761-73. https://doi.
Latha PG, Panikkar KR. Inhibition of Chemical Carcinogenesis in Mice
org/10.1016/j.bmc.2006.08.002 PMid:16919962.
32.
Kemmerer J, Zhang HZ. The discovery and mechanism of action of novel
Shakoori A.R, Ali SS, Saleem MA. Effect of six months feeding of cypermethrin
tumor-selective and apoptosis-inducing 3, 5-diaryl-1,2,4-oxadiazole series
https://doi.org/10.1002/jbt.2570030107.
28.
using a chemical genetics approach. Mol Cancer Ther. 2005;4(5):135-37.
33.
El-Emam. Synthesis, antimicrobial, and anti-inflammatory activities of novel
Insecticide “Spinosad” on Male Albino Rats Int. J Agri Biol. 2007;9(2):342-46.
2-(1-adamantyl)-5-substituted-1, 3, 4-oxadiazoles and 2-(1-adamantylamino)-
Shakoori AR, Aslam H, Sabir H, Ali SS. Effect of prolonged administration of
5-substituted-1,3,4-thiadiazoles. Eur J Med Chem. 2007;42(2):235-42.
Biologica. 1999;40:1-2.
https://doi.org/10.1016/j.ejmech.2006.10.003 PMid:17129641.
34.
Oludotun AP, Udo EE, Mohammad E. Abdel-Hamid, Varghese R. Synthesis
El-Bakary AS, Abdel FF, Abdel G, Mohamed MS, Attia I. Effect of Dimethoate
and antibacterial activity of novel 5-(4-methyl-1H-1, 2,3-triazole) methyl
on some Haematological Parameters of Toad Bufo regularis. J King Saud
oxazolidinones.
Unvi Agric Sci. 1995;1:85-95.
org/10.1016/j.ejmech.2009.03.024 PMid:19376613.
PICTORIAL ABSTRACT
About Authors
Dr. Jagadish Singh: Is working
as Asst. Professor, Institute of
Pharmaceutical
sciences
Guru
Ghasidas Vishwavidyalaya, Bilaspur,
C G (India). Research area (Interest):
Synthetic Medicinal Chemistry and
Photochemistry.
Evaluation
of
Anticancer, Antidiabetic, Antimicrobial
activities.
He has published more
than 10 international peer revived
publications as well as 13 national
publications.
Dr. Tapan Kumar Maity: Is working
as
Professor,
Department
of
Pharmaceutical Technology, Jadavpur
University. Research area (Interest):
Synthetic Medicinal Chemistry and
Photochemistry. He has more than
25 years of teaching and research
experience which is highlighted in
different national and international
journals.
268
Adnan AK, El-Brollosy NR, A-Deeb OA, Elsayed EH, Tarek M, Ali AI,
Mansour SA, Mossa AH, Heikal TM. Haematoxicity of a New Natural
Insceticides (Cyhalothrin/Karate) on the blood and Liver of Rabbites. Folia
29.
Katayoun AJ, Nicole ME, Wang YJ, Maliartchouk S, Archer SP, Qiu L, Brand R,
org/10.1016/S0304-3835(98)00140-2.
on the blood and liver of albino rats. J Biochem Toxicol. 1988;3(1):59-72.
27.
Nilantha S, Shailaja Kasibhatla BN, Pervin A, Wang Y, Claassen G, Tseng B,
PMid:20716929 PMCid:PMC2835890.
by Ixora Coccinea. Flowers Cancer Lett. 1998;130:197-02. https://doi.
26.
Sebrell WHJ, Harris RS. Tocopherols. In: The Vitamins: Chemistry,
Eur
J
Med
Chem.
2009;44(8):3217-27.
https://doi.
SUMMARY
• A series of 2, 5-disubstituted 1, 3, 4-Oxadiazole
derivatives (4A-4G) have been synthesized with
the help of different aromatic Benzaldehyde and
final compounds were characterized by FT-IR, 1H
NMR and Mass spectroscopy.
• The anticancer study was investigated against
Ehrlich Ascites Carcinoma (EAC) bearing albino
mice. The synthesized (4A-4G) compounds were
administered intraperitoneally at dose of 20-25
mg/kg; body weight per day for 7 days after 24
hour of tumor inoculation in mice.
• The standard compound used was 5-FU (20 mg/
kg; body, weight). Synthesized compounds (4A4G) remarkably decreased the body weight, tumor
volume, packed cell volume, viable cell count and
increased in tumor weight (%) inhibition, tumor
cells (%) inhibition, the life span, nonviable cell
count of EAC tumor bearing mice when compared
with the control group. The liver section of EAC
treated control group (II) was compared with the
drug treated groups (III-X).
• The histopathological observations of test groups
suggested that normal architecture of liver nucleus,
parenchyma, and hepatic cells were regenerated,
which was damaged in EAC control group.
• All the synthesized compounds (4A-4G) showed
significant anticancer activity in EAC bearing mice
which encourages us to develop/improve similar
other compounds and test them for their anticancer activity.
Indian Journal of Pharmaceutical Education and Research | Vol 51 | Issue 2 | Apr-Jun, 2017
Partha et al.: Synthesis and Evaluation of Anticancer Activity of 1, 3, 4-Oxadiazole Derivatives
Dr. Partha Pratim Roy: Is working as Asst. Professor, Institute of Pharmaceutical sciences Guru
Ghasidas Vishwavidyalaya, Bilaspur, C G (India). Research area (Interest): QSAR/ QSTR modeling
and drug design. He has more than 25 international peer revived publications.
Miss Shalini bajaj: Is working as research fellow Institute of Pharmaceutical sciences Guru
Ghasidas Vishwavidyalaya, Bilaspur, C G (India).
Cite this article: Roy PP, Bajaj S, Maity TK, Singh J. Synthesis and Evaluation of Anticancer Activity of 1, 3,
4-Oxadiazole Derivatives against Ehrlich Ascites Carcinoma Bearing Mice and Their Correlation with Histopathology
of Liver. Indian J of Pharmaceutical Education and Research. 2017;51(2):260-9.
Indian Journal of Pharmaceutical Education and Research | Vol 51 | Issue 2 | Apr-Jun, 2017
269